Overview

A First Time in Human Study of GSK586529 in Healthy Volunteers

Status:
Completed
Trial end date:
2008-04-11
Target enrollment:
Participant gender:
Summary
A single blind, randomized, placebo-controlled, crossover study in twenty four healthy male subjects. Subjects will be divided into two cohorts with alternate panel design. The study is investigating the safety, tolerability and pharmacokinetics of single oral escalating doses of GSK586529.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline